Dec 31, 2020
In this Encore episode, Stacey Richter talks with Chris Sloan, associate principal at Avalere Health, about how Medicare Part D plans became addicted to drug rebates — and what happens to premiums, PBMs, and pharma pricing if a proposal to eliminate those rebates actually takes effect.
WHAT YOU’LL LEARN
✅ Why...
Dec 24, 2020
In this Encore episode, Stacey Richter talks with AJ Loiacono, CEO of Capital Rx, about pharmaceutical contracting, PBMs, pharmacies, employers, and the HHS rebate proposal aimed at eliminating kickbacks to middlemen.
WHAT YOU’LL LEARN
✅ What the HHS proposal to eliminate rebate safe harbor actually changes
✅ Why...
Dec 17, 2020
In this inbetweenisode, Stacey Richter pulls together the wisdom of Relentless Health Value guests from throughout 2020 to reveal a common thread running through nearly every conversation about fixing health care.
WHAT YOU’LL LEARN
✅ Why patients so often fall through the cracks when their providers, payers, and...
Dec 10, 2020
In Episode 303, Stacey Richter talks with Anna Kaltenboeck, senior health economist and program director for the Drug Pricing Lab at Memorial Sloan Kettering, about QALYs — the “ruler” used to measure the value of a drug so society has a consistent benchmark for what to pay.
WHAT YOU’LL LEARN
✅ What a QALY...
Dec 3, 2020
In Episode 302, Stacey Richter talks with Blake McKinney, MD, ER physician and cofounder/CMO of CirrusMD, about what’s really wrong with the way we argue about telehealth — and why the site of care matters far less than the agency behind it.
WHAT YOU’LL LEARN
✅ Why telehealth “failures” are often really...